Dexamethasone sodium phosphate sustained release - Taiwan Liposomal Company
Alternative Names: Dexamethasone sustained release - Taiwan Liposomal Company; TLC-599Latest Information Update: 10 Jan 2025
At a glance
- Originator Taiwan Liposome Company
- Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoarthritis
Most Recent Events
- 10 Jan 2025 Dexamethasone sodium phosphate sustained release is still in phase-III trials for Osteoarthritis in USA and Australia (Intra-articular)
- 23 Nov 2023 Interim safety and efficacy data from a phase III EXCELLENCE trial in osteoarthritis released by Taiwan Liposome Company
- 10 Nov 2023 Efficacy and adverse events data from a phase III EXCELLENCE trial in osteoarthritis presented at the ACR Convergence 2023 (ACR/ARP-2023)